SUBSCRIBE
SUBSCRIBE
News   Drug Development

Endocyte, Inc. Initiates Phase 1 Trial of EC0489 for Treatment of Refractory or Metastatic Solid Tumors

May 6, 2009 | 
1 min read
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte Inc., has announced the initiation of a Phase 1 clinical trial with EC0489, a folate-targeted anti-cancer drug for the treatment of refractory or metastatic solid tumors.
Clinical research Phase 1
MORE ON THIS TOPIC
Business or economic growth concept with arrow icons on wooden cubes on blue background
Earnings
Moderna maintains 10% growth target despite Phase 3 norovirus miss
July 31, 2026
 · 
4 min read
 · 
Gabrielle Masson
complex messy management, bureaucracy,red tape,organization and innovation,business disruption, complicated business process
FDA
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
July 30, 2026
 · 
5 min read
 · 
Michael Gibney
Sky sunset anime background with clouds, that dance across the horizon, creating a breathtaking and serene backdrop. Cartoon vector cumulonimbus cloudscape, heaven, nature peaceful dusk landscape
Earnings
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
July 30, 2026
 · 
4 min read
 · 
Gabrielle Masson
Pandoras box with smoke on a wooden background
Earnings
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
July 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor